Hypertension – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：398頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hypertension – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Hypertension - Pipeline Review, H2 2012', provides an overview of the Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. 'Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hypertension.
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Hypertension - Pipeline Review, H2 2012', provides an overview of the Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. 'Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hypertension.
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Hypertension Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Hypertension 15
Hypertension Therapeutics under Development by Companies 17
Hypertension Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Bayer AG 65
Medivir AB 66
NicOx SA 67
Compugen Ltd. 68
Palatin Technologies, Inc. 69
Arena Pharmaceuticals, Inc. 70
BTG International Ltd 71
Chelsea Therapeutics, Inc. 72
Cytokinetics, Inc 73
Yuhan Corporation 74
XOMA Ltd. 75
Hanall Pharmaceutical Co., Ltd. 76
Ahn-Gook Pharmaceutical Co., Ltd. 77
LG Life Sciences, Ltd 78
DiaMedica Inc. 79
Simcere Pharmaceutical Group 80
Proteo, Inc. 81
axxonis Pharma AG 82
AFFiRiS AG 83
Respiratorius AB 84
IMMD Inc. 85
Ardelyx, Inc. 102
Ascendis Pharma A/S 103
Aristo Pharmaceuticals Ltd. 104
MicroDose Therapeutx, Inc. 105
Vicore Pharma AB 106
Serodus AS 107
Hypertension – Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Route of Administration 110
Assessment by Molecule Type 113
Drug Profiles 116
Edarbi - Drug Profile 116
DasKloster 1000-01 - Drug Profile 117
Tasigna - Drug Profile 119
BAY 63-2521 - Drug Profile 121
APD811 - Drug Profile 123
Angiotensin Therapeutic Vaccine - Drug Profile 125
DSP-8153 - Drug Profile 126
NBT-485 - Drug Profile 127
EUR 1000 - Drug Profile 128
LCZ-696 - Drug Profile 129
LCZ-696 - Drug Profile 131
QTI-571 - Drug Profile 133
Macitentan - Drug Profile 135
Iroxanadine - Drug Profile 137
OA2H - Drug Profile 139
PL-3994 - Drug Profile 140
QGC001 - Drug Profile 142
Northera - Drug Profile 143
BIA 5-1058 - Drug Profile 145
CGEN-856 - Drug Profile 146
CGEN-857 - Drug Profile 148
AT-877 - Drug Profile 149
UT-15C SR - Drug Profile 150
CK-2018509 - Drug Profile 152
CoVaccine HT - Drug Profile 153
HL040 - Drug Profile 155
Elafin - Drug Profile 156
DP-3005 - Drug Profile 158
MetPril - Drug Profile 159
SER100 - Drug Profile 160
RLX-030 - Drug Profile 162
Cell Based Gene Therapy - Drug Profile 164
N-Nitro L-arginine-methylester - Drug Profile 165
MD-0701 - Drug Profile 166
MD-0701 - Drug Profile 167
Carvedilol - Drug Profile 168
Selexipag - Drug Profile 169
Milrinone - Drug Profile 171
Warfarin - Drug Profile 172
Vardenafil - Drug Profile 174
Y-Secretase Inhibitor - Drug Profile 175
Obeticholic acid - Drug Profile 176
XL550 - Drug Profile 178
KM 732 - Drug Profile 180
Potassium - Drug Profile 181
HPT-C/D-3G - Drug Profile 182
Fenofibrate - Drug Profile 183
SPP1234 - Drug Profile 184
Chlorthalidone + Amiloride - Drug Profile 185
RHB-101 - Drug Profile 186
SPP800 series - Drug Profile 187
Ramipril - Drug Profile 188
Renin Inhibitors - Drug Profile 190
Sodium Nitroprusside - Drug Profile 191
Rostafuroxin - Drug Profile 192
Losartan + Hydrochlorothiazide - Drug Profile 193
Xenical - Drug Profile 194
YH-IMD1 - Drug Profile 195
Natrecor - Drug Profile 196
Dexmedetomidine - Drug Profile 198
Dichloroacetate - Drug Profile 200
Tetrahydrobiopterin - Drug Profile 202
Losartan - Drug Profile 203
Lisinopril - Drug Profile 204
Nitroprusside - Drug Profile 205
Sevoflurane - Drug Profile 206
BMS-823778 - Drug Profile 225
Atorvastatin - Drug Profile 227
S-474474 - Drug Profile 228
AG SCT101 - Drug Profile 229
AG SDT102 - Drug Profile 230
AG SFT103 - Drug Profile 231
Spironolactone - Drug Profile 232
Octreolin - Drug Profile 233
HL 007 - Drug Profile 235
HL 007 - Drug Profile 236
Losartan - Drug Profile 237
Amlodipine + Losartan + Hydrochlorothiazide - Drug Profile 238
AIR001 - Drug Profile 239
CKD-828 - Drug Profile 240
Lercanidipine + Valsartan - Drug Profile 242
S90652 - Drug Profile 243
Candesartan + Nifedipine + Metoprolol - Drug Profile 244
Lisinopril + Nifedipine + Metoprolol - Drug Profile 246
Carvedilol + Lisinopril - Drug Profile 248
MK5478 - Drug Profile 249
ACT-280778 - Drug Profile 251
SPP1193 - Drug Profile 252
CK-2019165 - Drug Profile 266
Eplerenone - Drug Profile 268
Allopurinol - Drug Profile 269
Nitroxyl Donor For PAH - Drug Profile 270
HL-056 - Drug Profile 271
HL053 - Drug Profile 272
ARBs + Statins - Drug Profile 273
HL051 - Drug Profile 274
Vaccine For Hypertension - Drug Profile 275
Candesartan BA - Drug Profile 276
Hydralazine + Amlodipine - Drug Profile 277
Polypill - Drug Profile 278
Somatostatin - Drug Profile 280
DM-204 - Drug Profile 281
NanoActive Telmisartan - Drug Profile 282
NanoActive Candesartan Cilexetil - Drug Profile 283
NanoActive Olmesartan Medoxomil - Drug Profile 284
Pterostilbene - Drug Profile 285
TAK-272 - Drug Profile 286
RDX5791 - Drug Profile 287
MT-3995 - Drug Profile 288
Ouabain And Adducin Antagonists - Drug Profile 289
MK-7145 - Drug Profile 290
AJH801 - Drug Profile 291
Amiloride - Drug Profile 292
Compound 21 - Drug Profile 293
Lercanidipine + Enalapril - Drug Profile 295
Drug For Hypertension - Drug Profile 296
nebivolol + valsartan - Drug Profile 297
MK4618 + Amlodipine - Drug Profile 298
GYY4137 - Drug Profile 299
CK-2018488 - Drug Profile 301
HCP0912 - Drug Profile 302
Menthol - Drug Profile 304
MP-157 - Drug Profile 305
CS-3150 - Drug Profile 306
Anti-Hypertensive Drug - Drug Profile 307
AGSAV301 - Drug Profile 308
Rosuvastatin Calcium + Olmesartan Medoxomil - Drug Profile 309
Anastrozole - Drug Profile 310
Tylerdipine Hydrochloride - Drug Profile 311
XOMA 985 - Drug Profile 312
Synthetic Dna-Based Therapy - Drug Profile 314
RDX008 - Drug Profile 315
KD-027 - Drug Profile 316
droxidopa - Drug Profile 317
TAK-536 + Amlodipine besilate - Drug Profile 318
PLX-PAH - Drug Profile 319
Selegiline + PDE-5 Inhibitor - Drug Profile 320
GTP-0125 - Drug Profile 321
CDRI-93/478 - Drug Profile 322
Amlodipine + Irbesartan - Drug Profile 324
nitric oxide - Drug Profile 325
Hypertension Therapeutics – Drug Profile Updates 327
Hypertension Therapeutics – Discontinued Products 360
Hypertension Therapeutics - Dormant Products 363
Hypertension – Product Development Milestones 376
Featured News & Press Releases 376
Appendix 386
Methodology 386
Coverage 386
Secondary Research 386
Primary Research 386
Expert Panel Validation 386
Contact Us 387
Disclaimer 387
List of Tables
Number of Products Under Development for Hypertension, H2 2012 26
Products under Development for Hypertension – Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..1) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Comparative Analysis by Late Stage Development, H2 2012 39
Comparative Analysis by Mid Clinical Stage Development, H2 2012 40
Comparative Analysis by Early Clinical Stage Development, H2 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 42
Products under Development by Companies, H2 2012 43
Products under Development by Companies, H2 2012 (Contd..1) 44
Products under Development by Companies, H2 2012 (Contd..2) 45
Products under Development by Companies, H2 2012 (Contd..3) 46
Products under Development by Companies, H2 2012 (Contd..4) 47
Products under Development by Companies, H2 2012 (Contd..5) 48
Products under Development by Companies, H2 2012 (Contd..6) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Bristol-Myers Squibb Company, H2 2012 54
United Therapeutics Corporation, H2 2012 55
Shionogi & Co., Ltd., H2 2012 56
Daiichi Sankyo Company, Ltd, H2 2012 57
Merck & Co., Inc., H2 2012 58
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 59
Takeda Pharmaceutical Company Limited, H2 2012 60
Plexxikon Inc., H2 2012 61
BioLineRx, Ltd., H2 2012 62
Mochida Pharmaceutical Co., Ltd., H2 2012 63
Novartis AG, H2 2012 64
Samyang Corporation, H2 2012 65
Actelion Ltd, H2 2012 66
Axcan Pharma Inc., H2 2012 67
Biocon Limited, H2 2012 68
Chong Kun Dang Pharmaceutical, H2 2012 69
Dong-A Pharmaceutical Co., Ltd., H2 2012 70
Forest Laboratories, Inc., H2 2012 71
Mitsubishi Tanabe Pharma Corporation, H2 2012 72
Nippon Shinyaku Co., Ltd., H2 2012 73
Recordati S.p.A., H2 2012 74
Sigma-Tau S.p.A., H2 2012 75
Bayer AG, H2 2012 76
Medivir AB, H2 2012 77
NicOx SA, H2 2012 78
Compugen Ltd., H2 2012 79
Palatin Technologies, Inc., H2 2012 80
Arena Pharmaceuticals, Inc., H2 2012 81
BTG International Ltd, H2 2012 82
Chelsea Therapeutics, Inc., H2 2012 83
Cytokinetics, Inc, H2 2012 84
Yuhan Corporation, H2 2012 85
XOMA Ltd., H2 2012 86
Hanall Pharmaceutical Co., Ltd., H2 2012 87
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 88
LG Life Sciences, Ltd, H2 2012 89
DiaMedica Inc., H2 2012 90
Simcere Pharmaceutical Group, H2 2012 91
Proteo, Inc., H2 2012 92
axxonis Pharma AG, H2 2012 93
AFFiRiS AG, H2 2012 94
Respiratorius AB, H2 2012 95
IMMD Inc., H2 2012 96
Global Health Ventures Inc., H2 2012 97
Aires Pharmaceuticals, Inc., H2 2012 98
Cardioxyl Pharmaceuticals, Inc., H2 2012 99
Mondobiotech Holding AG, H2 2012 100
Asahi Kasei Pharma, H2 2012 101
QUANTUM GENOMICS Corp., H2 2012 102
Intercept Pharmaceuticals, Inc., H2 2012 103
Adeona Pharmaceuticals, Inc., H2 2012 104
Diakron Pharmaceuticals, Inc., H2 2012 105
Biolink Group AS, H2 2012 106
Ikaria Inc., H2 2012 107
Bial - Portela & Ca, S.A., H2 2012 108
Northern Therapeutics, Inc., H2 2012 109
Pharnext SAS, H2 2012 110
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 111
Cellceutix Pharmaceuticals, Inc., H2 2012 112
Ardelyx, Inc., H2 2012 113
Ascendis Pharma A/S, H2 2012 114
Aristo Pharmaceuticals Ltd., H2 2012 115
MicroDose Therapeutx, Inc., H2 2012 116
Vicore Pharma AB, H2 2012 117
Serodus AS, H2 2012 118
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Stage and Route of Administration, H2 2012 123
Assessment by Stage and Molecule Type, H2 2012 126
Hypertension Therapeutics – Drug Profile Updates 338
Hypertension Therapeutics – Discontinued Products 371
Hypertension Therapeutics – Discontinued Products (Contd..1) 372
Hypertension Therapeutics – Discontinued Products (Contd..2) 373
Hypertension Therapeutics – Dormant Products 374
Hypertension Therapeutics – Dormant Products (Contd..1) 375
Hypertension Therapeutics – Dormant Products (Contd..2) 376
Hypertension Therapeutics – Dormant Products (Contd..3) 377
Hypertension Therapeutics – Dormant Products (Contd..4) 378
Hypertension Therapeutics – Dormant Products (Contd..5) 379
Hypertension Therapeutics – Dormant Products (Contd..6) 380
Hypertension Therapeutics – Dormant Products (Contd..7) 381
Hypertension Therapeutics – Dormant Products (Contd..8) 382
Hypertension Therapeutics – Dormant Products (Contd..9) 383
Hypertension Therapeutics – Dormant Products (Contd..10) 384
Hypertension Therapeutics – Dormant Products (Contd..11) 385
Hypertension Therapeutics – Dormant Products (Contd..12) 386
List of Figures
Number of Products under Development for Hypertension, H2 2012 26
Products under Development for Hypertension – Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 35
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Route of Administration, H2 2012 121
Assessment by Stage and Route of Administration, H2 2012 122
Assessment by Molecule Type, H2 2012 124
Assessment by Stage and Molecule Type, H2 2012 125
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Hypertension Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Hypertension 15
Hypertension Therapeutics under Development by Companies 17
Hypertension Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Bayer AG 65
Medivir AB 66
NicOx SA 67
Compugen Ltd. 68
Palatin Technologies, Inc. 69
Arena Pharmaceuticals, Inc. 70
BTG International Ltd 71
Chelsea Therapeutics, Inc. 72
Cytokinetics, Inc 73
Yuhan Corporation 74
XOMA Ltd. 75
Hanall Pharmaceutical Co., Ltd. 76
Ahn-Gook Pharmaceutical Co., Ltd. 77
LG Life Sciences, Ltd 78
DiaMedica Inc. 79
Simcere Pharmaceutical Group 80
Proteo, Inc. 81
axxonis Pharma AG 82
AFFiRiS AG 83
Respiratorius AB 84
IMMD Inc. 85
Ardelyx, Inc. 102
Ascendis Pharma A/S 103
Aristo Pharmaceuticals Ltd. 104
MicroDose Therapeutx, Inc. 105
Vicore Pharma AB 106
Serodus AS 107
Hypertension – Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Route of Administration 110
Assessment by Molecule Type 113
Drug Profiles 116
Edarbi - Drug Profile 116
DasKloster 1000-01 - Drug Profile 117
Tasigna - Drug Profile 119
BAY 63-2521 - Drug Profile 121
APD811 - Drug Profile 123
Angiotensin Therapeutic Vaccine - Drug Profile 125
DSP-8153 - Drug Profile 126
NBT-485 - Drug Profile 127
EUR 1000 - Drug Profile 128
LCZ-696 - Drug Profile 129
LCZ-696 - Drug Profile 131
QTI-571 - Drug Profile 133
Macitentan - Drug Profile 135
Iroxanadine - Drug Profile 137
OA2H - Drug Profile 139
PL-3994 - Drug Profile 140
QGC001 - Drug Profile 142
Northera - Drug Profile 143
BIA 5-1058 - Drug Profile 145
CGEN-856 - Drug Profile 146
CGEN-857 - Drug Profile 148
AT-877 - Drug Profile 149
UT-15C SR - Drug Profile 150
CK-2018509 - Drug Profile 152
CoVaccine HT - Drug Profile 153
HL040 - Drug Profile 155
Elafin - Drug Profile 156
DP-3005 - Drug Profile 158
MetPril - Drug Profile 159
SER100 - Drug Profile 160
RLX-030 - Drug Profile 162
Cell Based Gene Therapy - Drug Profile 164
N-Nitro L-arginine-methylester - Drug Profile 165
MD-0701 - Drug Profile 166
MD-0701 - Drug Profile 167
Carvedilol - Drug Profile 168
Selexipag - Drug Profile 169
Milrinone - Drug Profile 171
Warfarin - Drug Profile 172
Vardenafil - Drug Profile 174
Y-Secretase Inhibitor - Drug Profile 175
Obeticholic acid - Drug Profile 176
XL550 - Drug Profile 178
KM 732 - Drug Profile 180
Potassium - Drug Profile 181
HPT-C/D-3G - Drug Profile 182
Fenofibrate - Drug Profile 183
SPP1234 - Drug Profile 184
Chlorthalidone + Amiloride - Drug Profile 185
RHB-101 - Drug Profile 186
SPP800 series - Drug Profile 187
Ramipril - Drug Profile 188
Renin Inhibitors - Drug Profile 190
Sodium Nitroprusside - Drug Profile 191
Rostafuroxin - Drug Profile 192
Losartan + Hydrochlorothiazide - Drug Profile 193
Xenical - Drug Profile 194
YH-IMD1 - Drug Profile 195
Natrecor - Drug Profile 196
Dexmedetomidine - Drug Profile 198
Dichloroacetate - Drug Profile 200
Tetrahydrobiopterin - Drug Profile 202
Losartan - Drug Profile 203
Lisinopril - Drug Profile 204
Nitroprusside - Drug Profile 205
Sevoflurane - Drug Profile 206
BMS-823778 - Drug Profile 225
Atorvastatin - Drug Profile 227
S-474474 - Drug Profile 228
AG SCT101 - Drug Profile 229
AG SDT102 - Drug Profile 230
AG SFT103 - Drug Profile 231
Spironolactone - Drug Profile 232
Octreolin - Drug Profile 233
HL 007 - Drug Profile 235
HL 007 - Drug Profile 236
Losartan - Drug Profile 237
Amlodipine + Losartan + Hydrochlorothiazide - Drug Profile 238
AIR001 - Drug Profile 239
CKD-828 - Drug Profile 240
Lercanidipine + Valsartan - Drug Profile 242
S90652 - Drug Profile 243
Candesartan + Nifedipine + Metoprolol - Drug Profile 244
Lisinopril + Nifedipine + Metoprolol - Drug Profile 246
Carvedilol + Lisinopril - Drug Profile 248
MK5478 - Drug Profile 249
ACT-280778 - Drug Profile 251
SPP1193 - Drug Profile 252
CK-2019165 - Drug Profile 266
Eplerenone - Drug Profile 268
Allopurinol - Drug Profile 269
Nitroxyl Donor For PAH - Drug Profile 270
HL-056 - Drug Profile 271
HL053 - Drug Profile 272
ARBs + Statins - Drug Profile 273
HL051 - Drug Profile 274
Vaccine For Hypertension - Drug Profile 275
Candesartan BA - Drug Profile 276
Hydralazine + Amlodipine - Drug Profile 277
Polypill - Drug Profile 278
Somatostatin - Drug Profile 280
DM-204 - Drug Profile 281
NanoActive Telmisartan - Drug Profile 282
NanoActive Candesartan Cilexetil - Drug Profile 283
NanoActive Olmesartan Medoxomil - Drug Profile 284
Pterostilbene - Drug Profile 285
TAK-272 - Drug Profile 286
RDX5791 - Drug Profile 287
MT-3995 - Drug Profile 288
Ouabain And Adducin Antagonists - Drug Profile 289
MK-7145 - Drug Profile 290
AJH801 - Drug Profile 291
Amiloride - Drug Profile 292
Compound 21 - Drug Profile 293
Lercanidipine + Enalapril - Drug Profile 295
Drug For Hypertension - Drug Profile 296
nebivolol + valsartan - Drug Profile 297
MK4618 + Amlodipine - Drug Profile 298
GYY4137 - Drug Profile 299
CK-2018488 - Drug Profile 301
HCP0912 - Drug Profile 302
Menthol - Drug Profile 304
MP-157 - Drug Profile 305
CS-3150 - Drug Profile 306
Anti-Hypertensive Drug - Drug Profile 307
AGSAV301 - Drug Profile 308
Rosuvastatin Calcium + Olmesartan Medoxomil - Drug Profile 309
Anastrozole - Drug Profile 310
Tylerdipine Hydrochloride - Drug Profile 311
XOMA 985 - Drug Profile 312
Synthetic Dna-Based Therapy - Drug Profile 314
RDX008 - Drug Profile 315
KD-027 - Drug Profile 316
droxidopa - Drug Profile 317
TAK-536 + Amlodipine besilate - Drug Profile 318
PLX-PAH - Drug Profile 319
Selegiline + PDE-5 Inhibitor - Drug Profile 320
GTP-0125 - Drug Profile 321
CDRI-93/478 - Drug Profile 322
Amlodipine + Irbesartan - Drug Profile 324
nitric oxide - Drug Profile 325
Hypertension Therapeutics – Drug Profile Updates 327
Hypertension Therapeutics – Discontinued Products 360
Hypertension Therapeutics - Dormant Products 363
Hypertension – Product Development Milestones 376
Featured News & Press Releases 376
Appendix 386
Methodology 386
Coverage 386
Secondary Research 386
Primary Research 386
Expert Panel Validation 386
Contact Us 387
Disclaimer 387
List of Tables
Number of Products Under Development for Hypertension, H2 2012 26
Products under Development for Hypertension – Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..1) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Comparative Analysis by Late Stage Development, H2 2012 39
Comparative Analysis by Mid Clinical Stage Development, H2 2012 40
Comparative Analysis by Early Clinical Stage Development, H2 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 42
Products under Development by Companies, H2 2012 43
Products under Development by Companies, H2 2012 (Contd..1) 44
Products under Development by Companies, H2 2012 (Contd..2) 45
Products under Development by Companies, H2 2012 (Contd..3) 46
Products under Development by Companies, H2 2012 (Contd..4) 47
Products under Development by Companies, H2 2012 (Contd..5) 48
Products under Development by Companies, H2 2012 (Contd..6) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Bristol-Myers Squibb Company, H2 2012 54
United Therapeutics Corporation, H2 2012 55
Shionogi & Co., Ltd., H2 2012 56
Daiichi Sankyo Company, Ltd, H2 2012 57
Merck & Co., Inc., H2 2012 58
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 59
Takeda Pharmaceutical Company Limited, H2 2012 60
Plexxikon Inc., H2 2012 61
BioLineRx, Ltd., H2 2012 62
Mochida Pharmaceutical Co., Ltd., H2 2012 63
Novartis AG, H2 2012 64
Samyang Corporation, H2 2012 65
Actelion Ltd, H2 2012 66
Axcan Pharma Inc., H2 2012 67
Biocon Limited, H2 2012 68
Chong Kun Dang Pharmaceutical, H2 2012 69
Dong-A Pharmaceutical Co., Ltd., H2 2012 70
Forest Laboratories, Inc., H2 2012 71
Mitsubishi Tanabe Pharma Corporation, H2 2012 72
Nippon Shinyaku Co., Ltd., H2 2012 73
Recordati S.p.A., H2 2012 74
Sigma-Tau S.p.A., H2 2012 75
Bayer AG, H2 2012 76
Medivir AB, H2 2012 77
NicOx SA, H2 2012 78
Compugen Ltd., H2 2012 79
Palatin Technologies, Inc., H2 2012 80
Arena Pharmaceuticals, Inc., H2 2012 81
BTG International Ltd, H2 2012 82
Chelsea Therapeutics, Inc., H2 2012 83
Cytokinetics, Inc, H2 2012 84
Yuhan Corporation, H2 2012 85
XOMA Ltd., H2 2012 86
Hanall Pharmaceutical Co., Ltd., H2 2012 87
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 88
LG Life Sciences, Ltd, H2 2012 89
DiaMedica Inc., H2 2012 90
Simcere Pharmaceutical Group, H2 2012 91
Proteo, Inc., H2 2012 92
axxonis Pharma AG, H2 2012 93
AFFiRiS AG, H2 2012 94
Respiratorius AB, H2 2012 95
IMMD Inc., H2 2012 96
Global Health Ventures Inc., H2 2012 97
Aires Pharmaceuticals, Inc., H2 2012 98
Cardioxyl Pharmaceuticals, Inc., H2 2012 99
Mondobiotech Holding AG, H2 2012 100
Asahi Kasei Pharma, H2 2012 101
QUANTUM GENOMICS Corp., H2 2012 102
Intercept Pharmaceuticals, Inc., H2 2012 103
Adeona Pharmaceuticals, Inc., H2 2012 104
Diakron Pharmaceuticals, Inc., H2 2012 105
Biolink Group AS, H2 2012 106
Ikaria Inc., H2 2012 107
Bial - Portela & Ca, S.A., H2 2012 108
Northern Therapeutics, Inc., H2 2012 109
Pharnext SAS, H2 2012 110
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 111
Cellceutix Pharmaceuticals, Inc., H2 2012 112
Ardelyx, Inc., H2 2012 113
Ascendis Pharma A/S, H2 2012 114
Aristo Pharmaceuticals Ltd., H2 2012 115
MicroDose Therapeutx, Inc., H2 2012 116
Vicore Pharma AB, H2 2012 117
Serodus AS, H2 2012 118
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Stage and Route of Administration, H2 2012 123
Assessment by Stage and Molecule Type, H2 2012 126
Hypertension Therapeutics – Drug Profile Updates 338
Hypertension Therapeutics – Discontinued Products 371
Hypertension Therapeutics – Discontinued Products (Contd..1) 372
Hypertension Therapeutics – Discontinued Products (Contd..2) 373
Hypertension Therapeutics – Dormant Products 374
Hypertension Therapeutics – Dormant Products (Contd..1) 375
Hypertension Therapeutics – Dormant Products (Contd..2) 376
Hypertension Therapeutics – Dormant Products (Contd..3) 377
Hypertension Therapeutics – Dormant Products (Contd..4) 378
Hypertension Therapeutics – Dormant Products (Contd..5) 379
Hypertension Therapeutics – Dormant Products (Contd..6) 380
Hypertension Therapeutics – Dormant Products (Contd..7) 381
Hypertension Therapeutics – Dormant Products (Contd..8) 382
Hypertension Therapeutics – Dormant Products (Contd..9) 383
Hypertension Therapeutics – Dormant Products (Contd..10) 384
Hypertension Therapeutics – Dormant Products (Contd..11) 385
Hypertension Therapeutics – Dormant Products (Contd..12) 386
List of Figures
Number of Products under Development for Hypertension, H2 2012 26
Products under Development for Hypertension – Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 35
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Route of Administration, H2 2012 121
Assessment by Stage and Route of Administration, H2 2012 122
Assessment by Molecule Type, H2 2012 124
Assessment by Stage and Molecule Type, H2 2012 125
